The COBRRA randomized trial that compared direct oral anticoagulants (DOACs) for acute venous thromboembolism (VTE), and ...
Philadelphia: The U.S. Federal Trade Commission is on the lookout for anticompetitive practices in the pharmaceutical ...
In an editorial, one expert said the choice of DOAC in VTE is “no longer a toss-up,” with apixaban the clear winner.
Spread the loveAs the pharmaceutical industry continues to evolve, marketers must stay abreast of the latest developments and public sentiment that can influence their strategies. As of March 16, 2026 ...
A trial directly comparing Eliquis and Xarelto - two commonly used blood-thinning drugs from the same class of medicines - ...
Apixaban conferred lower bleeding risk during a 3-month period compared with rivaroxaban in patients with acute venous ...
Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the ...
The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results